Browsing by Author "Nazal L."

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Evaluation of patients with virus C hepatitis treated with direct-acting antivirals in the Chilean public systemHepatitis crónica por virus C. Evaluación de los pacientes tratados con antivirales de acción directa en el sistema público de Chile
    (Springer International Publishing, 2021) Mezzano G.; Aguirre H.; Pena A.; Gomez F.; Nazal L.; Arab J.P.; Roblero J.P.
    © 2021 Sociedad Medica de Santiago. All rights reserved.Background: Direct-acting antivirals (DAA) allowed a radical change in the treatment of hepatitis C virus (HCV), achieving the elimination of the virus or sustained viral response (SVR) in > 95% of patients, with good tolerance and few adverse effects. Aim: To characterize the treated population and evaluate the efficacy of DAA treatment in the Chilean public health system. Material and Methods: Retrospective analysis of data sheets of patients with chronic HCV infection collected by the Ministry of Health of Chile between 2016 and May 2019. Results: Two hundred and fifty-five patients with a mean age of 59 years (51% males) were collected. Genotype 1b was predominant, 72% patients had a diagnosis of cirrhosis at the beginning of treatment. Sofosbuvir-Velpatasvir was predominantly used in 56%. SVR was achieved in 92% of cases, only 4% persisted with detectable load at 24 weeks. A significant decrease in alanine aminotransferase values (88 and 31 U/L respectively, p < 0.01) and a significant increase in plasma albumin (3.7 and 3.9 mg/dl respectively, p = 0.02) were observed. The comparative analysis of MELD-Na before and after treatment did not show a significant variation (10.8 and 10.4 respectively, p = 0.34). Conclusions: These patients treated with DAAs presented SVR rates comparable with national and international data.